AI-POD Clinical Validation Study for Obese Patients

The clinical validation study of the AI-POD instruments (risk score, CDSS, Citizen App) is designed as a prospective, multicentre observational study. Obese patients (BMI >30 kg/m2) with suspected CVD who are scheduled for a cardiac CT scan (consisting of calcium scoring and coronary CT angiography) will be included in the study. This clinically indicated cardiac CT scan will serve as a baseline examination, and a second cardiac CT scan will be performed after a follow-up period of 2 years. Both cardiac CT examinations will be performed on a photon-counting CT system (PCCT). In addition to the CT data, clinical data (anthropometry and physical parameters such as body weight, height, age, gender, BMI, waist circumference, waist-to-hip ratio, body impedance analysis, cardiovascular risk factors, medication, previous interventions and operations) will be collected, symptoms and results of echocardiography to determine left ventricular function) as well as laboratory data on (subclinical) inflammation (hsCRP, leukocytes, monocyte activation), lipid disorders (HDL, LDL, total cholesterol, triacylglycerides), glucose homeostasis (HbA1c, fasting glucose, HOMA index), liver and kidney function (creatinine, GFR, GOT/ALAT, GPT/ASAT) are collected at a total of 5 visits over 2 years. Half of all included patients will also be randomised to receive access to the Citizen app and a separate fitness tracker device to record the following data: Activity data such as step count, heart rate, height, weight, gender, age, waist circumference circumference, nutritional data such as calorie intake, nicotine, alcohol, sleep.

Inclusion criteria

• Age greater than or equal to 45 years at the time of signing informed consent
• BMI greater than or equal to 30 kg/m2
• Patients with suspected CVD (>15% pretest probability [ESC guidelines]), referred for cardiac CT examinations (consisting of coronary calcium scoring and coronary CT angiography)
• Informed consent of the patient

Exclusion criteria

• Any of the following CV conditions within 2 months prior to study inclusion: myocardial infarction, stroke,
• Hospitalization for unstable angina pectoris or transient ischemic attack or due to congestive heart failure.
• Planned coronary, carotid, or peripheral artery revascularisation known on the day of inclusion
• Presently classified NYHA IV heart failure
• Having uncontrolled diabetes mellitus (HbA1c ≥ 11%) at day of inclusion
• Having uncontrolled hypertension (SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg) as measured at inclusion
• Having severe renal impairment measured as an eGFR < 30 mL/min/1.73 m2 at inclusion
• Alanine aminotransferase (ALT) or alkaline phosphatase (APT) level < 3.0 x the upper limit of normal (ULN)for the reference range
• Total bilirubin level >1.5 x the ULN for the reference range
• History of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
• Previous organ transplantation or awaiting an organ transplant
• Pregnancy or breastfeeding